Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Page 1
Development and validation of health system performance measures for opioid use disorder in British Columbia, Canada.
Nosyk B, Min JE, Pearce LA, Zhou H, Homayra F, Wang L, Piske M, McCarty D, Gardner G, O'Briain W, Wood E, Daly P, Walsh T, Henry B. Nosyk B, et al. Among authors: pearce la. Drug Alcohol Depend. 2022 Apr 1;233:109375. doi: 10.1016/j.drugalcdep.2022.109375. Epub 2022 Feb 24. Drug Alcohol Depend. 2022. PMID: 35231716
CONCLUSIONS: We identified a range of priorities to improve the quality of care for PWOUD, with critical gaps in linkage to care through acute care settings and long-term engagement in OAT. The proposed measures can be derived for geographic and clinical subgroups and upda …
CONCLUSIONS: We identified a range of priorities to improve the quality of care for PWOUD, with critical gaps in linkage to care through acu …
Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial.
Pearce LA, McClure LA, Anderson DC, Jacova C, Sharma M, Hart RG, Benavente OR; SPS3 Investigators. Pearce LA, et al. Lancet Neurol. 2014 Dec;13(12):1177-85. doi: 10.1016/S1474-4422(14)70224-8. Epub 2014 Oct 23. Lancet Neurol. 2014. PMID: 25453457 Free PMC article. Clinical Trial.
There was no interaction between assigned antiplatelet groups and assigned blood pressure target groups and change over time (p=0.196). INTERPRETATION: Cognitive function is not affected by short-term dual antiplatelet treatment or blood pressure reduction in fairly young …
There was no interaction between assigned antiplatelet groups and assigned blood pressure target groups and change over time (p=0.196). INTE …
Clinical correlates of infarct shape and volume in lacunar strokes: the Secondary Prevention of Small Subcortical Strokes trial.
Asdaghi N, Pearce LA, Nakajima M, Field TS, Bazan C, Cermeno F, McClure LA, Anderson DC, Hart RG, Benavente OR; SPS3 Investigators. Asdaghi N, et al. Among authors: pearce la. Stroke. 2014 Oct;45(10):2952-8. doi: 10.1161/STROKEAHA.114.005211. Epub 2014 Sep 4. Stroke. 2014. PMID: 25190442 Free PMC article. Clinical Trial.
CONCLUSIONS: In patients with recent lacunar stroke, vascular risk factor profile was similar among the different infarct shapes and sizes. Infarct size correlated with worse short-term functional outcome. Neither shape nor volume was predictive of stroke recurrence. ...
CONCLUSIONS: In patients with recent lacunar stroke, vascular risk factor profile was similar among the different infarct shapes and sizes. …
The relevance of living supports on antiplatelet adherence and trial participation: the SPS3 trial.
Lewis BL, Pearce LA, Field TS, White CL, Benavente OR; SPS3 Investigators. Lewis BL, et al. Among authors: pearce la. Int J Stroke. 2014 Jun;9(4):443-8. doi: 10.1111/ijs.12267. Epub 2014 Mar 24. Int J Stroke. 2014. PMID: 24661819 Free PMC article. Clinical Trial.
Number of medications and Stroke Specific Quality of Life scale score may be more indicative of likelihood of trial participation and acceptance of long-term antiplatelet regimen....
Number of medications and Stroke Specific Quality of Life scale score may be more indicative of likelihood of trial participation and accept …
Effect of addition of clopidogrel to aspirin on mortality: systematic review of randomized trials.
Palacio S, Hart RG, Pearce LA, Benavente OR. Palacio S, et al. Among authors: pearce la. Stroke. 2012 Aug;43(8):2157-62. doi: 10.1161/STROKEAHA.112.656173. Stroke. 2012. PMID: 22826359 Free PMC article. Review.
There was no significant increase in mortality with the combination therapy either in 4 short-term (14 days-3 months; OR, 0.93; 95% CI, 0.87-0.99) or in 7 long-term (>3 months; hazard ratio, 0.97; 95% CI, 0.91-1.04) trials after 1 long-term trial (the SPS3 …
There was no significant increase in mortality with the combination therapy either in 4 short-term (14 days-3 months; OR, 0.93; 95% C …
Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks.
Aguilar MI, Hart R, Pearce LA. Aguilar MI, et al. Among authors: pearce la. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD006186. doi: 10.1002/14651858.CD006186.pub2. Cochrane Database Syst Rev. 2007. PMID: 17636831 Review.
Both oral anticoagulants and antiplatelet agents have proven effective for stroke prevention in most patients at high risk for vascular events, but primary stroke prevention in patients with non-valvular AF potentially merits separate consideration because of the suspected cardio …
Both oral anticoagulants and antiplatelet agents have proven effective for stroke prevention in most patients at high risk for vascular even …
Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas.
Hart RG, Tonarelli SB, Pearce LA. Hart RG, et al. Among authors: pearce la. Stroke. 2005 Jul;36(7):1588-93. doi: 10.1161/01.STR.0000170642.39876.f2. Epub 2005 Jun 9. Stroke. 2005. PMID: 15947271 Review.
We review the incidence, risk factors, and predictors of ICH in patients receiving long-term anticoagulation or antiplatelet therapy. SUMMARY OF REVIEW: ICH rates range from 0.3% to 0.6% per year during oral anticoagulation in recent reports. ...
We review the incidence, risk factors, and predictors of ICH in patients receiving long-term anticoagulation or antiplatelet therapy. …
Transient ischemic attacks in patients with atrial fibrillation: implications for secondary prevention: the European Atrial Fibrillation Trial and Stroke Prevention in Atrial Fibrillation III trial.
Hart RG, Pearce LA, Koudstaal PJ. Hart RG, et al. Among authors: pearce la. Stroke. 2004 Apr;35(4):948-51. doi: 10.1161/01.STR.0000120741.34866.1D. Epub 2004 Feb 26. Stroke. 2004. PMID: 14988571 Clinical Trial.
BACKGROUND AND PURPOSE: Transient ischemic attacks (TIAs) are infrequent in patients with atrial fibrillation, and little is known about the long-term prognosis and response to antithrombotic therapy. METHODS: This study was a pooled analysis of participants in 2 randomize …
BACKGROUND AND PURPOSE: Transient ischemic attacks (TIAs) are infrequent in patients with atrial fibrillation, and little is known about the …
Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials.
Hart RG, Palacio S, Pearce LA. Hart RG, et al. Among authors: pearce la. Stroke. 2002 Nov;33(11):2722-7. doi: 10.1161/01.str.0000035735.49388.4a. Stroke. 2002. PMID: 12411668 Review.
Data conflict about whether early use of heparin/heparinoid reduced early recurrent ischemic stroke but are consistent regarding its lack of overall benefit on long-term functional outcome. Modest benefits for reduction of early recurrent stroke and functional outcome were …
Data conflict about whether early use of heparin/heparinoid reduced early recurrent ischemic stroke but are consistent regarding its lack of …